Ionis Pharmaceuticals Inc To Discuss Eplontersen NEURO-TTRansform 66-Week Results Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst : Congrats on the data here it looks like a very competitive profile to what's already on the market from one of your peers. Obviously, cross draw comparisons forward with our caveats yet, we do them anyway. So I'm referring to Helios and our future. I think one of the investor questions I think at Ionis is just when you look at the deltas, so the separation between drug and placebo across the different time scales here. It does appear to look at least a little bit numerically [be go] With them future than it does for the eplontersen data set. I know that there's different time points involved here. There's different placebo responses, different patient populations. I'm just wondering like how valid those cross-trial comparisons are in your point of view? And what the key sort of things are to look for in terms of differences in patient demographics that we might want to look for when we're interpreting these changes.